Personal information

No personal information available

Activities

Collapse all

Employment (3)

European Medicines Agency: Amsterdam, Noord-Holland, NL

2021-09-01 to present | Biostatistician
Employment
Source: Self-asserted source
Florian Lasch

Hannover Medical School: Hannover, DE

2016-01-01 to 2021-05-31 (Institute of Biostatistics)
Employment
Source: Self-asserted source
Florian Lasch

European Medicines Agency: Amsterdam, NL

2019-04-01 to 2020-03-31 (Biostatistics support office)
Employment
Source: Self-asserted source
Florian Lasch

Works (21)

Applying the estimand framework to clinical pharmacology trials with a case study in bioequivalence

British Journal of Clinical Pharmacology
2025-02 | Journal article
DOI: 10.1111/bcp.16347
Contributors: Helle Lynggaard; Sue McKendrick; Mark Baird; Essam Kerwash; Vivian Lanius; Florian Lasch; David Wright
Source: check_circle
Crossref

Demonstration of Major Therapeutic Advantage From a Review of EU Conditional Marketing Authorizations in Oncology and Hematology

Clinical Pharmacology & Therapeutics
2025-01-07 | Journal article
DOI: 10.1002/cpt.3554
Contributors: Florian Lasch; Joana R. B. Carvalho; Caroline Pothet
Source: check_circle
Crossref

Estimands in CNS trials – A review of strategies for addressing intercurrent events

Contemporary Clinical Trials Communications
2024-04 | Journal article
DOI: 10.1016/j.conctc.2024.101266
Contributors: Lisa Mészáros; Florian Lasch; Bruno Delafont; Lorenzo Guizzaro
Source: check_circle
Crossref

Type‐I‐error rate inflation in mixed models for repeated measures caused by ambiguous or incomplete model specifications

Pharmaceutical Statistics
2023-09 | Journal article
DOI: 10.1002/pst.2328
Part of ISSN: 1539-1604
Part of ISSN: 1539-1612
Contributors: Sebastian Haeckl; Armin Koch; Florian Lasch
Source: Self-asserted source
Florian Lasch

Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
2022-12 | Journal article
DOI: 10.1055/a-1853-8291
Part of ISSN: 1438-9029
Part of ISSN: 1438-9010
Contributors: Jens Vogel-Claussen; Florian Lasch; Benjamin-Alexander Bollmann; Katharina May; Alexander Kuhlmann; Gerald Schmid-Bindert; Rudolf Kaaks; Jörg Barkhausen; Sabine Bohnet; Martin Reck
Source: Self-asserted source
Florian Lasch

Estimators for handling COVID‐19‐related intercurrent events with a hypothetical strategy

Pharmaceutical Statistics
2022-06-28 | Journal article
DOI: 10.1002/pst.2244
Part of ISSN: 1539-1604
Part of ISSN: 1539-1612
Source: Self-asserted source
Florian Lasch

The Impact of COVID‐19 on the Initiation of Clinical Trials in Europe and the United States

Clinical Pharmacology & Therapeutics
2022-05 | Journal article
DOI: 10.1002/cpt.2534
Part of ISSN: 0009-9236
Part of ISSN: 1532-6535
Source: Self-asserted source
Florian Lasch

A Simulation Study on the Estimation of the Effect in the Hypothetical Scenario of No Use of Symptomatic Treatment in Trials for Disease-Modifying Agents for Alzheimer’s Disease

Statistics in Biopharmaceutical Research
2022-04-29 | Journal article
DOI: 10.1080/19466315.2022.2055633
Part of ISSN: 1946-6315
Source: Self-asserted source
Florian Lasch

Microbiota-associated Risk Factors for Clostridioides difficile Acquisition in Hospitalized Patients: A Prospective, Multicentric Study

Clinical Infectious Diseases
2021-11-02 | Journal article
DOI: 10.1093/cid/ciaa871
Part of ISSN: 1058-4838
Part of ISSN: 1537-6591
Contributors: Philipp Solbach; Patrick Chhatwal; Sabrina Woltemate; Evelina Tacconelli; Michael Buhl; Ingo B Autenrieth; Maria J G T Vehreschild; Nathalie Jazmati; Markus Gerhard; Christoph K Stein-Thoeringer et al.
Source: Self-asserted source
Florian Lasch

Potential impact of COVID‐19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA‐TICS study

Pharmaceutical Statistics
2021-05 | Journal article
DOI: 10.1002/pst.2100
Contributors: Florian Lasch; Lorenzo Guizzaro; Lukas Aguirre Dávila; Kirsten Müller‐Vahl; Armin Koch
Source: check_circle
Crossref

Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients

Trials
2020-12 | Journal article
DOI: 10.1186/s13063-020-04522-9
Contributors: Verena Scheper; Melanie Schmidtheisler; Florian Lasch; Heiko von der Leyen; Armin Koch; Jana Schwieger; Andreas Büchner; Anke Lesinski-Schiedat; Thomas Lenarz
Source: check_circle
Crossref

Single‐Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: a Retrospective Cohort Study of Centralised European Marketing Authorizations between 2010‐2019

Clinical Pharmacology & Therapeutics
2020-06-23 | Journal article
DOI: 10.1002/cpt.1965
Part of ISSN: 0009-9236
Part of ISSN: 1532-6535
Source: Self-asserted source
Florian Lasch

Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale

Frontiers in Cardiovascular Medicine
2020-04-09 | Journal article
DOI: 10.3389/fcvm.2020.00051
Part of ISSN: 2297-055X
Source: Self-asserted source
Florian Lasch

<p>Simplified Measurement of Maximum Strength After Knee Surgery: Application-Based Knee-Training Device Compared to Isokinetic Testing</p>

Open Access Journal of Sports Medicine
2020-01 | Journal article
DOI: 10.2147/OAJSM.S214598
Contributors: Hauke Horstmann; Pascal Medico; Florian Lasch; Werner Krutsch; Thomas Sanjay Weber-Spickschen
Source: check_circle
Crossref

Improving Maximal Strength in the Initial Postoperative Phase After Anterior Cruciate Ligament Reconstruction Surgery: Randomized Controlled Trial of an App-Based Serious Gaming Approach

JMIR Serious Games
2020-01-24 | Journal article
DOI: 10.2196/14282
Contributors: Jan-Dierk Clausen; Niclas Nahen; Hauke Horstmann; Florian Lasch; Werner Krutsch; Christian Krettek; Thomas Sanjay Weber-Spickschen
Source: check_circle
Crossref

Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols

Pharmaceutical Statistics
2019-11 | Journal article
DOI: 10.1002/pst.1964
Contributors: Sebastian Häckl; Armin Koch; Florian Lasch
Source: check_circle
Crossref

Improving Maximal Strength in the Initial Postoperative Phase After Anterior Cruciate Ligament Reconstruction Surgery: Randomized Controlled Trial of an App-Based Serious Gaming Approach (Preprint)

2019-04-05 | Other
DOI: 10.2196/preprints.14282
Contributors: Jan-Dierk Clausen; Niclas Nahen; Hauke Horstmann; Florian Lasch; Werner Krutsch; Christian Krettek; Thomas Sanjay Weber-Spickschen
Source: check_circle
Crossref

Commentary: On the levels of patient selection in registry-based randomized controlled trials

Trials
2019-02-04 | Journal article
DOI: 10.1186/s13063-019-3214-x
Part of ISSN: 1745-6215
Source: Self-asserted source
Florian Lasch
grade
Preferred source (of 2)‎

New research strategy with ambiguous implications: A comment on “Planning future studies based on the conditional power of a meta-analysis”

Statistics in Medicine
2018-04-15 | Journal article
DOI: 10.1002/sim.7595
Part of ISSN: 0277-6715
Source: Self-asserted source
Florian Lasch

Free-breathing Dynamic (19)F Gas MR Imaging for Mapping of Regional Lung Ventilation in Patients with COPD.

Radiology
2017-10 | Journal article
DOI: 10.1148/radiol.2017170591
PMID: 28972817
Contributors: Gutberlet M; Kaireit TF; Voskrebenzev A; Lasch F; Freise J; Welte T; Wacker F; Hohlfeld JM; Vogel-Claussen J
Source: Self-asserted source
Florian Lasch via Europe PubMed Central

A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients.

Orphanet journal of rare diseases
2017-05 | Journal article
DOI: 10.1186/s13023-017-0655-8
PMID: 28545482
PMC: PMC5445360
Contributors: Lasch F; Weber K; Chao MM; Koch A
Source: Self-asserted source
Florian Lasch via Europe PubMed Central
How many people are using ORCID?